Is it possible that one patient may again experience a response to abiraterone acetate withdrawal during an abiraterone acetate rechallenge?

摘要

We previously reported one case of biochemical and metabolic response after abiraterone acetate (AA) withdrawal in a 78-yr-old man affected by metastatic castration-resistant prostate cancer who received AA after docetaxel failure [1]. After AA discontinuation in October 2012, in January 2013 we observed a prostate-specific antigen (PSA) decrease from 192.84 ng/ml to a nadir of 15.68 ng/ml and a significant decrease in standard uptake value (SUV) (ASUV_(max) -35%) of all known bone and lymph node metastases on 18F-choline positron emission tomography (cPET) (Fig. 1).